AzTrials
AzTrials

Varicose VeinsNCT03326219

Endoveneous Histologic Study

A study testing Clarivein in people with Varicose Veins, run by Rijnstate Hospital at 1 site in Netherlands.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

A new technique, mechanochemical endovenous ablation (MOCA), using the ClariVein ® system is recently developed. To date, histopathological data after mechanochemical endovenous ablation are not known. The aim of this study is the histopathological analysis of venous injury using mechanochemical endovenous ablation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Varicose Veins
What is being tested?
Clarivein
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteNetherlands
Study dates
Jan 2017to Dec 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Elective indication for leg amputation
  • Peripheral arterial disease
  • Age > 18 years
  • Written informed consent

Who cannot join

  • Patient is incapable of informed consent
  • Pregancy and lactation
  • Previous surgical or endovenous treatment of the greater saphenous vein in the amputed leg
  • Great saphenous vein is used for bypass surgery
  • INR > 1.8
  • ASA 5

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Rijnstate

    Arnhem, Gelderland, 68ooTA

Other trials in Netherlands

About this study

Official title: Histopathological Study of the Vena Saphena Magna After Mechanochemical Endoveneous Ablation

A new technique, mechanochemical endovenous ablation (MOCA), using the ClariVein ® system is recently developed. To date, histopathological data after mechanochemical endovenous ablation are not known.

The aim of this study is the histopathological analysis of venous injury using mechanochemical endovenous ablation.

Read the detailed description

Background:

Varicose veins are a common problem in the Western world. Epidemiological studies show that one quarter of adults have some form of varicose veins. Women are two to three times more affected than men. The prevalence of varicose veins increases steadily with age and is among the top ten of the complaints that people visit their General Practitioner. The main risk factors are prolonged standing or sitting, pregnancy, gender and age. The symptoms of varicose veins are variable and range from cosmetic complaints to venous ulcers.

Stripping of the great saphenous vein(GSV) has been the golden standard for GSV insufficiency for a long time. It is performed under regional or general anesthesia and has a high recurrence rate of 18-40% at 5 years. In addition, the procedure leads to significant postoperative symptoms, especially pain, hematoma and the risk of injury to the saphenous nerve.

In recent years, endovenous techniques have been developed for the treatment of primary GSV insufficiency. Particularly laser endovenous ablation (EVLA) and radiofrequency ablation (VNUS) became accepted technologies and are widely applied in practice. These thermal-based techniques have the advantage that the surgery can be performed with local anesthesia. In addition, endovenous techniques cause less hematoma, pain, and have superior cosmetics and earlier resumption of normal activities/work compared to the conventional surgical stripping.

Endothermal techniques use heat, which has potential risk to damage surrounding tissues. For this reason, patients are treated with tumiscence anesthesia, requiring multiple punctures around the vein. Most patients experience tumiscence anesthesia as unpleasant. Despite the tumiscence anesthesia, patients may still observe postoperative pain, which may last for weeks.

Laser energy is absorbed and converted into intraluminal heat. This process causes steam bubbles, as described by Proebstle. In previous studies, intraluminal and extraluminal temperature measurements were done during endovenous laser ablation. In addition, acute pathological changes after endovenous laser ablation is studied in a recent study. The loss of laser energy was confined to the inner part of the media. No perivascular damage was seen. However, 1% of patients treated with endovenous laser ablation has nerve damage or paresthesias. It suggests that perivascular damage to some extent still exists.

The effects of foam sclerosis appear to be limited to the endothelium and tunica media of the vein wall. Pathological changes occur rapidly within the first 2 minutes after treatment. After 30 minutes intimal detachment of the tunica media, and the formation of microthrombi are detected. The addition of a balloon injury of the vessel wall prior to foam sclerosis, results in a higher percentage of endothelial damage. However, in practice, the clinical results of foam sclerosis disappointing. The occlusionrate from 1 to 5 years were 81 and 73% in a recent meta-analysis.

A new technique, mechanochemical endovenous ablation (MOCA), using the ClariVein ® system is recently developed. The first studies show that MOCA a safe and effective treatment for varicose veins. This technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique . Tumiscence anesthesia is redundant and complications that occur in thermal endovenous techniques, such as pain, hematoma formation, induration and paresthesias could be reduced. To date, histopathological data after mechanochemical endovenous ablation are not known.

Objective of the study:

The aim of this study is the histopathological analysis of venous injury using mechanochemical endovenous ablation

Study design:

The Endovenous Histology study is a histopathological study on the effects of mechanochemical endovenous ablation. The studycentre will be:

  • Rijnstate Hospital, Arnhem.

5 patients with irreversible tissue damage to the lower extremities based on atherosclerotic peripheral vascular disease will be included in the study Endovenous Histology, after signing informed consent. All patients included, are scheduled for an elective upper or underleg amputation. The preprocedural status will be determined by height, weight, comorbidities, ASA classification, medications, previous vascular surgery and venous duplex of the VSM.

Subsequently 5 patients are treated with MOCA of the VSM to the amputation level prior to the amputation under general or spinal anesthesia.

Conditions
Varicose Veins
Being tested
Clarivein
Keywords
MOCA, VSM, Clarivein, Histological
Medical subject headings
Varicose Veins

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ClariveinProcedure or surgery

    The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .

Study groups in NCT03326219
Study groupRoleWhat they receive
Aethoxysklerol clarivein during leg ampOtherClarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation
Receives: Procedure: Clarivein

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Occlusion of the with Clarivein treated vein

    Occlusion of the with the Clarivein (Aethoxysklerol) treated vein, check wheter or not treatment was succesfull.

    Measured: 2 years of inclusion and analyzation

  2. Depth of damage inside and/or outside the venous wall

    Depth of damage inside and/or outside the venous wall is to check whether or not the venous wall is damaged due to the Clarivein treatment

    Measured: 2 years of inclusion and analyzation

Secondary outcomes (3)
  1. Analysis of intraluminal clot / scar

    After excision of the treated vein of the amputated leg it will be analysed on intraluminal clot/scar

    Measured: 2 years of inclusion and analyzation

  2. Morphological changes of the saphenous nerve due to damage of treatment

    Analyses of the changes of the saphenous nerve in the treated area (amputated lef) due to the Clarivein treatment.

    Measured: 2 years of inclusion and analyzation

  3. Perivascular damage resulting from treatment

    Analyses of the perivascular damage in the amputated leg as a result of the treatment

    Measured: 2 years of inclusion and analyzation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Oct 2017
  2. Study startJan 2017
  3. Primary completionDec 2019 (estimated)
  4. Study completionDec 2020 (estimated)

Why it stopped: Difficulty finding eligible patients

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03326219
Sponsor's protocol ID
NL38948.091.12
Status last verified
Nov 2018
First submitted
13 Oct 2017
Last updated
28 Nov 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Clarivein in people with Varicose Veins, run by Rijnstate Hospital at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 28 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Occlusion of the with Clarivein treated vein (time frame: 2 years of inclusion and analyzation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in